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Abstract
Background: Non-typeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae are major causes of
bacterial acute otitis media (AOM). Data regarding AOM are limited in Latin America. This is the first active
surveillance in a private setting in Venezuela to characterize the bacterial etiology of AOM in children < 5 years of
age.
Methods: Between December 2008 and December 2009, 91 AOM episodes (including sporadic, recurrent and
treatment failures) were studied in 87 children enrolled into a medical center in Caracas, Venezuela. Middle ear
fluid samples were collected either by tympanocentesis or spontaneous otorrhea swab sampling method. Standard
laboratory and microbiological techniques were used to identify bacteria and test for antimicrobial resistance. The
results were interpreted according to Clinical Laboratory Standards Institute (CLSI) 2009 for non-meningitis isolates.
All statistical analyses were performed using SAS 9.1 and Microsoft Excel (for graphical purposes).
Results: Overall, bacteria were cultured from 69.2% (63 of the 91 episodes); at least one pathogen (S. pneumoniae,
H. influenzae, S. pyogenes or M. catarrhalis) was cultured from 65.9% (60/91) of episodes. H. influenzae (55.5%; 35/63
episodes) and S. pneumoniae (34.9%; 22/63 episodes) were the most frequently reported bacteria. Among H.
influenzae isolates, 62.9% (22/35 episodes) were non-capsulated (NTHi) and 31.4% (11/35 episodes) were capsulated
including types d, a, c and f, across all age groups. Low antibiotic resistance for H. influenzae was observed to
amoxicillin/ampicillin (5.7%; 2/35 samples). NTHi was isolated in four of the six H. influenzae positive samples
(66.7%) from recurrent episodes.
Conclusions: We found H. influenzae and S. pneumoniae to be the main pathogens causing AOM in Venezuela.
Pneumococcal conjugate vaccines with efficacy against these bacterial pathogens may have the potential to
maximize protection against AOM.
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Background
Acute otitis media (AOM) is one of the most frequently
diagnosed bacterial infections in children following
nasopharyngeal colonization [1]. It results in frequent
pediatric visits both in the developed [2] and developing
world [3]. Approximately, three in four children develop
at least one episode of AOM by 3 years of age, [4] with
peak incidences observed among 6-18 month-old chil-
dren [2]. A report on the epidemiology of AOM by
Block and colleagues [5] showed that 64% of children
had experienced their first episode by 6 months, and
86% by 1 year of age; 31% had > 3 episodes in < 12
months of age. AOM is, thus, one of the main causes of
childhood morbidity in both developed and developing
countries [6]. The estimated annual disease burden of
AOM ranges between 8,200,000-12,900,000 cases among
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ibbean [7]. In Venezuela, approximately 100,000-130,000
AOM cases per year (2004-2007) are reported in chil-
dren < 5 years of age (Ministerio del Poder Popular para
la Salud. Gobierno Bolivariano de Venezuela, Personal
communication, 2010).
AOM is a multi-pathogen disease [8]. Streptococcus
pneumoniae (S. pneumoniae) and non-typeable Haemo-
philus influenzae (NTHi) have consistently been
reported as the two major bacterial pathogens responsi-
ble for AOM, [9-11] identified in up to 80% of cases.
Other regularly reported bacterial pathogens include
Moraxella catarrhalis (M. catarrhalis) and Streptococcus
pyogenes (S. pyogenes) [11]. S. pneumoniae has been
shown to be responsible for 43.8%-61.4% of all bacterial
AOM cases in Latin America [12-14]. H. influenzae has,
however, emerged as the most frequently recovered bac-
terial pathogen in recent studies [13,15]. AOM caused
by NTHi has been particularly associated with older age
groups and recurrent disease [11]. Recurrent to chronic
AOM may predispose to chronic suppurative otitis
media (CSOM) in a third of cases [16]. Globally, 65-330
million people may suffer from CSOM [17].
Recurrent disease in children has important implica-
tions for AOM treatment. Although some cases resolve
spontaneously, the majority require antibiotic treatment
for early recovery. AOM constitutes the primary motive
for the prescription of antibiotics in children [18]. The
increasing use of these antibiotics may be acting as a
selective pressure driving antibiotic resistance [19].
AOM is the primary cause of antibiotic consumption in
Latin America and the Caribbean [20]. Antibiotic con-
sumption in Latin America is highest in Argentina and
Venezuela [21]. High prevalence of drug-resistant patho-
gens like penicillin-resistant S. pneumoniae and b-lacta-
mase producing or other ampicillin-resistant H.
influenzae have become major factors in complicating
the management of AOM [22]. Efforts to prevent infec-
tious diseases through vaccination may be able to
reduce the demand for antibiotics in the community
and the selective persistence of nasopharyngeal bacterial
pathogens [23].
Pneumoccocal conjugate vaccines (PCVs) have been
shown to be safe and effective in preventing invasive
pneumococcal disease (IPD) in children [24,25]. The 7-
valent pneumococcal vaccine (PCV-7; Prevnar™/Preve-
nar™, Pfizer/Wyeth, US) was introduced into the US
public immunization strategy in 2000 and has demon-
strated noticeable efficacy against IPD [26,27]; 57% (95%
CI: 44-67) efficacy against vaccine-type pneumococcal
AOM [28] and overall 7% (95%CI: 4.1-9.7) efficacy
against clinical AOM episodes [24]. Wide use of PCV-7
led to a relative shift in the proportion of pathogens
causing persistent AOM was observed (decrease in S.
pneumoniae and an increasing predominance of NTHi)
[10]. Furthermore, with widespread vaccination, the pre-
dominant cause of remaining cases of pneumococcal
disease became non-vaccine serotypes of S. pneumoniae
[29,30], due to changing antimicrobial resistance pat-
terns and secular trends. There are two new PCVs
licensed recently in Venezuela. The 10-valent pneumo-
coccal/H. influenzae protein D conjugated vaccine
(PHiD-CV, Synflorix™, GlaxoSmithKline [GSK] Biologi-
cals, Rixensart, Belgium) has 8 of the 10 serotypes con-
jugated to a recombinant form of protein D of H.
influenzae. A randomized, double-blind study with an
11-valent prototype vaccine relying on the protein D
carrier provides evidence that proteinD-containing vac-
cines may offer additional protection (35%) against
AOM episodes caused by both pneumococcus and H.
influenzae [31]. A 13-valent pneumococcal vaccine for-
mulation (PCV-13) is also available.
In Venezuela, Haemophilus influenzae type B was
introduced into the expanded program of immunization
in 2000 [32]. Pneumoccocal conjugate vaccines are not
indicated for universal vaccination, however since 2004,
PCV-7 has been gradually introduced into private prac-
tice. Data on AOM in Latin America are limited and no
there are no data on AOM etiology in Venezuela. This
study thus provides novel data on the bacterial etiology
of AOM and the associated serotypes in Venezuelan
children. This study assessed the microbiology of AOM
cases, antibiotic susceptibility pattern of the middle ear
pathogens obtained from these cases, and the proportion
of AOM episodes that may be vaccine-preventable with
new pneumococcal vaccines recently licensed.
Methods
Study design and subjects
We conducted a prospective epidemiological study
within a routine, private clinical setting in a medical
center in Caracas, Venezuela from December 2008 to
December 2009. Children ≥3 months and < 5 years of
age, visiting physician/pediatrician clinics for AOM and
for whom a MEF sample was available, were enrolled in
the study. We included children presenting with one of
the general signs of otalgia/irritability, conjunctivitis,
fever and either Paradise’s criteria (bulging, diffused or
localized inflamed tympanic membranes) or sponta-
neous otorrhea (< 24 h). Exclusion criteria included:
children hospitalized at the time of the diagnosis or
treatment of AOM, presenting with a new episode of
AOM but having received antibiotic treatment in the
previous 72 h for a different illness, those who had
received antibiotic by the physician/ear, nose and throat
(ENT) specialist prior to tympanocentesis and those
with otorrhea for > 24 h or with otitis media with effu-
sion (not AOM).
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recruitment: - Children with a new episode of AOM (<
72 h of onset) who were yet to receive antibiotic therapy
for the episode, and - Children with a diagnosis of AOM
within 48-72 h before study enrolment, who had
received antibiotic therapy, but remained symptomatic
at the time of study entry (treatment failures).
A child could be enrolled multiple times in the study
whenever he/she reported a new episode. A case was
considered as a new episode if there was a 30-day symp-
tom-free interval since the resolution of the first epi-
sode. A recurrent AOM episode was the third or greater
new episode within the last 6 months or the fourth or
greater new episode within the last 12 months.
The primary endpoints were occurrence of H. influen-
zae, S. pneumoniae, M. catarrhalis and S. pyogenes iso-
lated from MEF samples. Secondary endpoints were
occurrence of H. influenzae and S. pneumoniae specific
serotypes from MEF samples and antimicrobial suscept-
ibility of all bacterial pathogens isolated from MEF
samples.
Written informed consent was obtained from the par-
ents/guardians of participating children before conduct-
ing any study-related procedures. We collected
demographic information including age and sex assuring
confidentiality for subjects enrolled.
Bacterial identification and characterization
Samples of MEF from all children were collected by an
ENT specialist by performing tympanocentesis or by
careful sampling of spontaneous otorrhoea (removal and
cleaning of the ear canal material and deep aspiration of
the MEF material via needle insertion).
Microbiology
MEF samples were inoculated into Amies transport
medium with charcoal [33], sent to the study laboratory
(Laboratorio Metropolitano) within 16-48 h, inoculated
onto chocolate and blood agar and incubated at 37°C in
a5 %C O 2 atmosphere. For identification, standard
guidelines described by the American Society of Micro-
b i o l o g yw e r eu s e da n dc o n f i r m e db yu s i n gN Ha n dG P
cards VITEK-2 compact system (bioMérieux™).
Clinical feature
A detailed medical history including symptoms, season-
ality, vaccination status for PCV and HiB, AOM epi-
sodes characteristics including recurrency, A clinical
examination was performed recording all data in the
study database.
Antibacterial susceptibility
Antimicrobial susceptibility was done using AST-P68
(bioMérieux™)f o rS. pneumoniae, standard methods
for H. influenzae and M. catarrhalis were according to
Clinical Laboratory Standards Institute (CLSI-M100-
S19) 2009 and for quality control, S. pneumoniae ATCC
49619 and H. influenzae ATCC 49247 y 49766 [34]
strains were used. Serotyping for S. pneumoniae was
done at the national reference laboratory, Laboratorio
de Microbiologia del Instituto Nacional de Higiene
“Rafael Rangel” using Quellung reaction following SIR-
EVA II guidelines [35]. H. influenzae isolates were con-
firmed by polymerase chain reaction (PCR) procedures
and b-lactamase testing (nitrocefin disk) was performed.
Statistical analyses
We performed the analyses only on the ATP cohort
(subjects meeting all eligibility criteria, complying with
the protocol-defined procedures, with no elimination
criteria during the study and for whom laboratory
results of the MEF samples was available). The study
results were presented as episodes of AOM.
We calculated the proportions of AOM caused by S.
pneumoniae, H. influenzae and other bacterial patho-
gens. Distribution analyses of S. pneumoniae and H.
influenzae serotypes by age, procedure and pneumococ-
cal vaccination status according to age (fully vaccinated,
partially vaccinated and unvaccinated) for AOM cases
were performed. We also determined seasonality of
AOM cases and other isolates. Qualitative variables,
including symptoms and vaccination, were compared to
explore differences among capsulated and non capsu-
lated H. influenzae status with the Fisher exact test. All
tests were 2 sided, and the level of significance was set
at p < 0.05.
All statistical analyses were performed using Statistical
Analysis System (SAS) version 9.1 (or higher) and
Microsoft Excel (for graphical purposes).
Ethics
The study was conducted according to Good Clinical
Practice guidelines, the Declaration of Helsinki and the
local rules and regulations of the country. All the study-
related documents were reviewed and approved by the
local Independent Ethics Committee/Institutional
Review Board and the study adhered to applicable local
guidelines.
Results
Demographic characteristics and sample description
We collected data on 92 episodes of AOM reported
from 87 enrolled children. Ninety-one episodes were
retained in the ATP (according-to-protocol) cohort due
to one child being enrolled more than once for the
same AOM episode. Only one of these episodes was
classified as a treatment failure. Of the 87 children
included in the ATP cohort, 84 reported a single
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reported three episodes. Any consecutive episode
occurred with an interval of > 30 days after the previous
episode.
The mean age of the children for all episodes was 28.3
months; the proportion of females was 51.6% (47/91 epi-
sodes) (Additional file 1: Table S1).
The majority of the episodes (57.2%; 52/91) were
reported in the 1-3 years age group; 30.8% (28/91 epi-
sodes) and 26.4% (24/91 episodes) occurred in the 12-23
months and 24-35 months age groups, respectively.
We collected one MEF (middle ear fluid) sample from
each of the 91 episodes. Most samples (90.1%; 82/91
episodes) were collected by tympanocentesis, while nine
samples (9.9%) were collected from spontaneous otor-
rhea episodes. Of the nine episodes with spontaneous
otorrhea, 18.2% (2/11), 17.9% (5/28) and 8.3% (2/24)
were distributed in the 3-11 months, 12-23 months and
24-35 months age groups, respectively.
Bacterial etiology of episodes
We observed pathogenic bacterial growth in 67.1% (55/
82 episodes) and 88.9% (8/9 episodes) of samples col-
lected by tympanocentesis and spontaneous otorrhoea,
respectively. Overall, bacteria were cultured from 69.2%
(63) of the 91 episodes; one treatment failure episode of
AOM did not show any bacterial growth. Overall, 65.9%
(60) of the episodes yielded positive cultures for at least
one of the four pathogenic bacteria. The most com-
monly isolated bacteria among MEF samples with bac-
terial growth were H. influenzae and S. pneumoniae,
detected in 55.5% (35/63) and 34.9% (22/63) of episodes,
respectively. Only 3.2% (2/63) episodes were positive for
S. pyogenes, and 1.6% (1/63 episodes) for M. catarrhalis.
No single episode was positive for both S. pneumoniae
and H. influenzae.
The highest number of positive episodes for at least
one of the four pathogenic bacteria under study was in
the 3-11 months age group (72.7%; 8/11 episodes); the
lowest number of positive episodes was found in the 24-
35 months age group (58.3%; 14/24 episodes). The most
frequently isolated bacteria across all age groups were
H. influenzae and S. pneumoniae (Figure 1).
Among episodes with spontaneous otorrhea, S. pneu-
moniae was isolated in three episodes, S. pyogenes in
two, H. influenzae in one episode; the remaining two
episodes corresponded to other agents.
Recurrent AOM episodes were reported for 5.4% (14/
91 episodes) during the study. We obtained bacterial
cultures from samples from 71.4% (10/14) of these
recurrent episodes. Of these, 6/10 were positive for H.
influenzae;3 / 1 0f o rS. pneumoniae and 1/10 was posi-
tive for M. catarrhalis.
Bacterial etiology by serotype
Most H. influenzae strains were non-capsulated (NTHi:
62.9%; 22/35 episodes). This was followed by serotype d
(17.1%; 6/35 episodes), a and c (each accounting for
5.7%; 2/35 episodes), and f (2.9%; 1/35 episodes). Two
samples (5.7%; 2/35 episodes) were reported as
unknown serotype.
Serotype 19A was the most frequently isolated S.
pneumoniae serotype (40.9%; 9/22 episodes) followed by
serotypes 6A, 11 and 15 (each accounting for 9.1%; 2/22
episodes), and 23 F and 7 C (each accounting for 4.5%;
1/22 episodes). Five samples (22.7%; 5/22 episodes) were
reported as unknown (Figure 2).
A similar trend of serotype distribution was observed
across the age groups for both H. influenzae and S.
pneumoniae.
Of the six H. influenzae positive samples from recur-
rent episodes, NTHi was isolated in four samples
(66.7%; 4/6 samples). The remaining two samples corre-
sponded to types c and a. The three S. pneumoniae
positive samples from recurrent episodes corresponded
to serotypes 7 C, 23 F and one was reported as
unknown. Of the 14 recurrent AOM episodes, the high-
est numbers of episodes were reported in the 24-35
months and 36-47 months age groups (5 episodes each);
three episodes were reported in the 12-23 months and
one episode in the 3-11 months age groups.
Common symptoms reported
Fever (65.9%; 60/91 episodes) and ear pain (57.1%; 52/91
episodes) were the most common symptoms reported
before the study visit and also during the study visit
(49.5%; 45/91 episodes and 56%; 51/91 episodes, for
fever and ear pain respectively). We did not observe sig-
nificant differences between capsulated and non-capsu-
lated H. influenzae for fever (68.2% vs. 72.7%; p = 0.78)
and pain (45.5% vs. 54.5%; p = 0.62).
Seasonal distribution of bacterial etiology of episodes
AOM episodes occurred throughout the year; the high-
est numbers of episodes were recorded for children
enrolled in 2009 (July: 14 episodes; March: 10 episodes).
The highest number of H. influenzae positive episodes
was in children enrolled in April and July (14.3% each;
5/35 episodes). At least one S. pneumoniae positive epi-
sode was reported for most months of the year -
between January and April, and July and December,
inclusive, the highest number of episodes being enrolled
in July (22.7%; 5/22 episodes) (Figure 3).
Vaccination status
About 80.2% (73/91 episodes) of episodes occurred in
children who received at least one dose of the PCV-7.
Naranjo et al. BMC Infectious Diseases 2012, 12:40
http://www.biomedcentral.com/1471-2334/12/40
Page 4 of 10Figure 1 Bacterial etiology of episodes by age (ATP Cohort). The simple bars represent the percentage of bacterial episodes in each age
group.
Figure 2 Bacterial etiology by serotypes (ATP Cohort). The stacked column bars represent the number of serotypes for each bacterial
positive episode.
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influenzae received at least one H. influenzae type b vac-
cine dose.
The percentage of episodes with positive cultures for
at least one of the four study bacteriawas 69.6% (32/46
episodes) in fully vaccinated children, 63% (17/27 epi-
sodes) in partially vaccinated and 57.1% (8/14 episodes)
in unvaccinated children.
More specifically for S. pneumoniae, the percentage of
culture positive episodes was 30.3% (10/33 episodes),
35.3% (6/17 episodes) and 40.0% (4/10 episodes) in the
fully vaccinated, partially vaccinated and unvaccinated
children, respectively. The percentage of H. influenzae
culture positive episodes were 63.6% (21/33 episodes) in
the fully vaccinated children, 52.9% (9/17 episodes) in
partially vaccinated and 40.0% (4/10 episodes) in unvac-
cinated children, respectively. We did not find signifi-
cant differences between capsulated and non-capsulated
H. influenzae or between fully vaccinated and partially/
unvaccinated groups (p = 0.38).
Antibacterial susceptibility
Among the 35 H. influenzae positive samples, 94.3%
(33/35) were sensitive to amoxicillin/ampicillin, 5.7% (2/
35) were resistant to amoxicillin/ampicillin and 2.9% (1/
35) showed intermediate resistance to cefuroxime. 25.7%
(9/35) samples showed resistance to trimethoprim/sulfa-
methoxazole. The two isolates resistant to amoxicillin/
ampicillin and susceptible to amoxicillin/clavulanate
were tested for b-lactamase activity with positive results
(n = 2).
Among the 22 S. pneumoniae positive samples, 77.3%
(17/22) were sensitive, 18.2% (4/22) and 4.5% (1/22) of
samples were intermediate and resistant to penicillin,
respectively (Figure 4). All S. pneumoniae isolates tested
except three were sensitive to amoxicillin and ampicillin
(86.4%; 19/22). Erythromycin resistance was reported in
33.3% (7/22) samples; 35% (7/22) of samples were resis-
tant to tetracycline and 45.5% (10/22) to trimethoprim/
sulfamethoxazole.
Of the nine samples positive for S. pneumoniae sero-
type 19A, 77.8% (7/9) were sensitive to penicillin and
intermediate resistance was observed for 22.2% (2/9)
samples. No resistance to penicillin was noted for this
serotype. No antibiotic resistance was observed to cefo-
taxime, chloramphenicol or levofloxacin.
Discussion
This is the first study to investigate the bacterial etiology
of AOM in a private setting in Venezuela. Our findings
are novel in that we identified non-capsulated and cap-
sulated H. influenzae as the main pathogens causing
Figure 3 Seasonal distribution of AOM episodes (ATP Cohort). The blue stacked line graph shows the number of AOM episodes enrolled in
each month and the simple bar graph shows the number of H. influenzae and S. pneumoniae episodes isolated each month.
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influenzae (55.5%) and S. pneumoniae (34.9%) were the
most commonly isolated bacte r i a .T h i si si n - l i n ew i t h
other studies who have reported these bacteria to be fre-
quently isolated in other Latin American countries
including Argentina [36], Chile [13], Costa Rica [12,37],
Mexico [38] and Colombia [39]. Following the introduc-
tion of PCV-7 and the inclusion of the vaccine into the
universal immunization program in the United States, a
significant decrease in the proportion of S. pneumoniae
and an increase in H. influenzae proportion among MEF
isolates have been reported (2003-2006) [40]. A similar
pattern was observed in the present study and has been
observed in previous studies [10,41] following introduc-
tion of the PCV. An increase in the occurrence of non-
PCV-7 S. pneumoniae serotypes has also been described
previously [42].
In the current analysis, we show that H. influenzae
isolated in Venezuelan children was most commonly
NTHi (62.9%). NTHi has previously been reported to be
associated with a history of recurrent AOM episodes,
treatment failure and AOM within two weeks of com-
pleting a course of any antibiotic [43]. The high preva-
lence of NTHi in this private setting could be explained
by the fact that vaccine coverage for PCV was consider-
ably high (63.6%). In this previous study, the authors
showed that NTHi was not only the most prevalent
cause of recurrent episodes of AOM but also of new
cases and was detected across all age groups [44]. This
finding differs from earlier reports of NTHi in children
2 years or older [11]. In our present study, most of the
episodes we reported were in children younger than 24
months; NTHi was the most prevalent type among all
age groups, including 3-11 month olds, who showed an
equal distribution with S. pneumoniae.
We also report the isolation of capsulated H. influen-
zae including types d, c, a and f, which has not been
reported previously. These were not only isolated in all
age groups, but also reported in recurrent episodes. In a
recent systematic review for Latin America, capsulated
types were not confirmed in MEF samples from AOM
etiology studies except for b type. This was also consis-
tent with the results from other studies in Europe, such
as France, where H. influenzae isolates were identified
as NTHi. This could be explained by the fact that naso-
pharyngeal colonization of encapsulated H influenzae is
uncommon, occurring only in 2-5% of children [45,46]
We found serotype 19A to be the most commonly iso-
lated S. pneumoniae serotype (40.9%) from children who
were fully vaccinated with the PCV, suggesting that
PCV-7 vaccination does not offer a high level of cross-
protection against 19A. Recently, in the US and other
countries the non-vaccine serotype 19A has been asso-
ciated with an increase in the proportions of IPD and
Figure 4 Penicillin resistance for S. pneumoniae isolates (ATP Cohort).S u s c e p t i b i l i t yo fe a c hS .p n e u m o n i a es e r o t y p et op e n i c i l l i nf o r
categories viz; sensitive, intermediate and resistant.
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terial pathogens in this present study were S. pyogenes
(2.2%) and M. catarrhalis (1.1%), similar to other studies
[36,48].
We observed a seasonal pattern of AOM in the pre-
sent study that was similar to that observed in a recent
study in Colombia [39]. We found that AOM episodes
were reported throughout the year, with the highest
number of episodes reported in July, corresponding to
the rainy season in Venezuela.
An increased use of antibiotics has been observed in
Latin American countries, predominantly in Venezuela
[21]. Antibiotic resistance to S. pneumoniae and H.
influenzae has become a serious public health issue,
more so in Latin America due to increased S. pneumo-
niae resistance to penicillin and other antibiotics [7].
Seven of nine S. pneumoniae 19A isolates were sensitive
to penicillin in our study, highlighting the low preva-
lence of penicillin-resistant serotype 19A. In the H.
influenzae isolates reported, 25.7% were resistant to tri-
methoprim-sulfamethoxazole and 5.7% to amoxicillin/
ampicillin. We did not observe antibiotic resistance to
amoxicillin/clavulanate, cefotaxime, chloramphenicol
and tetracycline. A limited occurrence of amoxicillin
resistance has been previously detected in another mul-
tinational study [49]. Hence, amoxicillin and amoxicil-
lin/clavulanate continue to be considered as appropriate
treatment options for AOM in children [50]. Reducing
antibiotic use by maximizing vaccination uptake may be
a useful strategy to eradicate antibiotic-resistant
serotypes.
PCVs could be an important tool in reducing the
AOM burden. Besides offering protection against the
vaccine serotypes, previous studies suggest that PCV7-
CRM provides cross-protection against the non-vac-
cine serotype 6A for IPD and AOM [28,51] and that
PCVs with different conjugation methods or carrier
proteins may provide modest (though non-significant)
protection against 19A disease [52]. Antibiotic resis-
tance and selection pressures are also likely to have an
impact on the efficacy of PCVs. Vaccines that may
protect against non-capsulated and capsulated H.
influenzae serotypes may also play an important role
to reduce the number of AOM episodes. Efficacies of
35.6% and 35.3% have previously been shown [31]
against all H. influenzae and NTHi otitis media epi-
sodes with a prototype pneumococcal vaccine conju-
gated to the H influenzae protein D. This protein is
present in capsulated and non-capsulated isolates and
hence may potentially protect against AOM episodes
caused by these agents. The proportions of pathogens
causing AOM and potentially targeted by each vaccine
formulation would be 55% for PHiD-CV and 19% for
PCV-13. However, it is important to note that no
efficacy or effectiveness data exist for either formula-
tion. Additionally, previous studies with the precursor
vaccines (PCV-7; 11-valent pneumococcal protein D
conjugate PHiD-CV predecessor vaccine) have demon-
strated efficacy of < 100% against the targeted patho-
gens [28,31]. The precise magnitude of protection is
therefore unknown.
This study is limited by a small sample size which
affects the precision of the estimates. In addition, the
enrolled children were recruited from a private center
and thus may not truly represent the Venezuelan popu-
lation. This is particularly important given the potential
differences in exposure and risk factors for otitis media
across the country.
Conclusions
In summary, this was the first active surveillance for
AOM etiology in Venezuela in a private setting in a
highly PCV vaccinated population. NTHi was the most
prevalent etiological agent, suggesting that protection
against NTHi is crucial for AOM prevention. Reduced
antibiotic use and vaccine with efficacy against H. influ-
enzae (beyond type b) and S. pneumoniae could be
effective strategies for preventing AOM disease among
children in Venezuela.
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